DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Ryvu Therapeutics SA
Weill Medical College of Cornell University
Novartis
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Arbeitsgemeinschaft medikamentoese Tumortherapie